Please wait while the formulary information is being retrieved.
DRUG IMAGES
No Image Available
The following indications for TRIAMCINOLONE ACETONIDE (triamcinolone acetonide) have been approved by the FDA:
Indications:
None.
Professional Synonyms:
None.
Indications:
None.
Professional Synonyms:
None.
The following dosing information is available for TRIAMCINOLONE ACETONIDE (triamcinolone acetonide):
Dermatologic preparations of triamcinolone acetonide are applied sparingly in thin films and are rubbed gently into the affected area 2-4 times daily. The 0.5% cream and 0.5%
ointment should be used only in the treatment of dermatoses which are refractory to treatment with lower concentrations. The 0.1 and 0.5%
creams are applied 2-3 times daily according to severity of the condition. When the aerosol is applied, an area about the size of the patient's hand is sprayed for about 2 seconds from a distance of about 7.5-15 cm 3 or 4 times daily.
Occlusive dressings may be used for severe or resistant dermatoses.
For use in the mouth, a small amount (about 0.6 cm) of the 0.1% paste is pressed to the lesion without rubbing until a thin film develops; a larger amount may be required to cover some lesions. The paste is applied at bedtime and, if necessary, 2 or 3 times daily, preferably after meals.
If substantial regeneration or repair of the oral tissues does not occur after 7 days of treatment, further investigation of the etiology of the oral lesions should be undertaken.
The route of administration and dosage of triamcinolone and its derivatives depend on the condition being treated and the response of the patient. IM therapy is generally reserved for patients who are not able to take the drug orally. Dosage for infants and children should be based on the severity of the disease and the response of the patient rather than on strict adherence to dosage indicated by age, body weight, or body surface area.
After a satisfactory response is obtained, dosage should be decreased in small decrements to the lowest level that maintains an adequate clinical response, and the drug should be discontinued as soon as possible. Patients should be continually monitored for signs that indicate dosage adjustment is necessary, such as remissions or exacerbations of the disease and stress (surgery, infection, trauma). One manufacturer recommends that an alternate-day dosage regimen be considered when long-term oral triamcinolone therapy is necessary.
However, most authorities state that only methylprednisolone, prednisolone, and prednisone have been proven to be suitable for alternate-day glucocorticoid therapy. Following long-term therapy, triamcinolone should be withdrawn gradually.
ointment should be used only in the treatment of dermatoses which are refractory to treatment with lower concentrations. The 0.1 and 0.5%
creams are applied 2-3 times daily according to severity of the condition. When the aerosol is applied, an area about the size of the patient's hand is sprayed for about 2 seconds from a distance of about 7.5-15 cm 3 or 4 times daily.
Occlusive dressings may be used for severe or resistant dermatoses.
For use in the mouth, a small amount (about 0.6 cm) of the 0.1% paste is pressed to the lesion without rubbing until a thin film develops; a larger amount may be required to cover some lesions. The paste is applied at bedtime and, if necessary, 2 or 3 times daily, preferably after meals.
If substantial regeneration or repair of the oral tissues does not occur after 7 days of treatment, further investigation of the etiology of the oral lesions should be undertaken.
The route of administration and dosage of triamcinolone and its derivatives depend on the condition being treated and the response of the patient. IM therapy is generally reserved for patients who are not able to take the drug orally. Dosage for infants and children should be based on the severity of the disease and the response of the patient rather than on strict adherence to dosage indicated by age, body weight, or body surface area.
After a satisfactory response is obtained, dosage should be decreased in small decrements to the lowest level that maintains an adequate clinical response, and the drug should be discontinued as soon as possible. Patients should be continually monitored for signs that indicate dosage adjustment is necessary, such as remissions or exacerbations of the disease and stress (surgery, infection, trauma). One manufacturer recommends that an alternate-day dosage regimen be considered when long-term oral triamcinolone therapy is necessary.
However, most authorities state that only methylprednisolone, prednisolone, and prednisone have been proven to be suitable for alternate-day glucocorticoid therapy. Following long-term therapy, triamcinolone should be withdrawn gradually.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for TRIAMCINOLONE ACETONIDE (triamcinolone acetonide):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for TRIAMCINOLONE ACETONIDE (triamcinolone acetonide):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 0 severe contraindications.
There are 0 moderate contraindications.
The following adverse reaction information is available for TRIAMCINOLONE ACETONIDE (triamcinolone acetonide):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 0 severe adverse reactions.
There are 0 less severe adverse reactions.
The following precautions are available for TRIAMCINOLONE ACETONIDE (triamcinolone acetonide):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
Precaution Exists
Precaution exists. (No data or inconclusive human data.) Use of this drug by breast feeding mothers should be evaluated carefully.
Precaution Exists
Precaution exists. (No data or inconclusive human data.) Use of this drug by breast feeding mothers should be evaluated carefully.
| Drug Name | Excretion Potential | Effect on Infant | Notes |
|---|---|---|---|
| Triamcinolone (nasal,inh,top,ophth) | Unknown. It is unknown whether the drug is excreted in human breast milk. | It is not known whether this drug has an adverse effect on the nursing infant. (No data or inconclusive human data) | Amount of systemic absorption unknown, caution advised |
| Triamcinolone (oral,inj) | Unknown. It is unknown whether the drug is excreted in human breast milk. | It is not known whether this drug has an adverse effect on the nursing infant. (No data or inconclusive human data) | Other systemic corticosteroids excreted; insufficient human data available |
No enhanced Geriatric Use information available for this drug.
Precaution Exists
Geriatric management or monitoring precaution exists.
Precaution Exists
Geriatric management or monitoring precaution exists.
| Drug Name | Narrative | REN | HEP | CARDIO | NEURO | PULM | ENDO |
|---|---|---|---|---|---|---|---|
| Triamcinolone | Cardiovascular-Caution in chronic heart failure patients due to sodium and water retention with glucocorticoid use. Endocrine-May cause hyperglycemia or worsen glucose control in diabetics. Longer term use may cause osteopenia or osteoporosis. Neuro/Psych-Avoid in older adults with or at high risk of delirium due to risk of inducing or worsening delirium. | N | N | Y | Y | N | Y |
| Triamcinolone(topical) | Skin-Elderly at increased risk of skin atrophy, ulceration, especially with existing decreased skin circulation. | N | N | N | N | N | N |
The following prioritized warning is available for TRIAMCINOLONE ACETONIDE (triamcinolone acetonide):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for TRIAMCINOLONE ACETONIDE (triamcinolone acetonide)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool